Dr. Rajasree P. Chowdry, MD | New ...

Dr. Rajasree P. Chowdry

Claim this profile

University Medical Center New Orleans

Studies Skin Cancer
Studies Kidney Cancer
5 reported clinical trials
16 drugs studied

Area of expertise

1Skin Cancer
Rajasree P. Chowdry has run 4 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
CD4 count positive
CD4 count negative
2Kidney Cancer
Rajasree P. Chowdry has run 2 trials for Kidney Cancer. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
University Medical Center New Orleans
Image of trial facility.
East Jefferson General Hospital

Clinical Trials Rajasree P. Chowdry is currently running

Image of trial facility.

Cabozantinib +/− Atezolizumab

for Advanced Kidney Cancer

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Recruiting0 awards Phase 2

More about Rajasree P. Chowdry

Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Rajasree P. Chowdry has experience with
  • Nivolumab
  • Carboplatin
  • Paclitaxel
  • Cabozantinib
  • Ipilimumab
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rajasree P. Chowdry specialize in?
Rajasree P. Chowdry focuses on Skin Cancer and Kidney Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are CD4 count positive.
Is Rajasree P. Chowdry currently recruiting for clinical trials?
Yes, Rajasree P. Chowdry is currently recruiting for 3 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Rajasree P. Chowdry has studied deeply?
Yes, Rajasree P. Chowdry has studied treatments such as Nivolumab, Carboplatin, Paclitaxel.
What is the best way to schedule an appointment with Rajasree P. Chowdry?
Apply for one of the trials that Rajasree P. Chowdry is conducting.
What is the office address of Rajasree P. Chowdry?
The office of Rajasree P. Chowdry is located at: University Medical Center New Orleans, New Orleans, Louisiana 70112 United States. This is the address for their practice at the University Medical Center New Orleans.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.